| Overview |
| bs-70721R |
| VEGFR-2 (Tyr-801) [conserved site], Phosphospecific Antibody |
| WB, ICC |
| The antibody detects a 180 kDa* band corresponding to VEGFR-2 in western blots of human endothelial cells treated with pervanadate, and shows strong reactivity toward recombinant human VEGFR-2. |
| Human, Mouse, Rat |
| Specifications |
| Unconjugated |
| Rabbit |
| Phospho-VEGFR-2 (Tyr-801) peptide (coupled to carrier protein) corresponding to amino acids surrounding Tyr-801 in human VEGFR-2. |
| Tyr-801 |
| Polyclonal |
| IgG |
| Antigen Affinity purification |
| PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| P35968 |
| KDR, flk-1, Vascular endothelial growth factor receptor 2 |
| Vascular endothelial growth factor receptor-2 (VEGFR-2/Flk-1/KDR) is the primary receptor for VEGF in endothelial cells. Other VEGFR family members, VEGFR-1 (Flt-1) and VEGFR-3 (Flt-4), can also transduce the intracellular signals of VEGF. However, the role of VEGFR-1 is observed mainly during embryonic angiogenesis and VEGFR-3 signaling may be restricted to specific types of endothelial cells. Major autophosphorylation sites of VEGFR-2 are located in the kinase insert domain (Tyr-951/996) and in the tyrosine kinase catalytic domain (Tyr-1054/1059). Other sites, Tyr-1175 and Tyr-1212 provide docking sites for downstream signaling molecules. Activation of VEGFR-2 also phosphorylates Tyr-801, leading to PI3-kinase-Akt activation and increases in endothelial nitric oxide synthase activity. Phosphorylation of mutliple sites in VEGFR-2 is required for downstream activation of several signaling pathways that control proliferation, chemotaxis, and sprouting during angiogenesis. |
| Application Dilution |
| WB |
1:300-5000 |
| ICC |
1:100-500 |
Powered by Bioz